Age-related alterations in muscle architecture are a signature of sarcopenia: the ultrasound sarcopenia index.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
08 2021
Historique:
revised: 23 03 2021
received: 21 01 2021
accepted: 03 05 2021
pubmed: 2 6 2021
medline: 26 11 2021
entrez: 1 6 2021
Statut: ppublish

Résumé

The assessment of muscle mass is a key determinant of the diagnosis of sarcopenia. We introduce for the first time an ultrasound imaging method for diagnosing sarcopenia based on changes in muscle geometric proportions. Vastus lateralis muscle fascicle length (Lf) and thickness (Tm) were measured at 35% distal femur length by ultrasonography in a population of 279 individuals classified as moderately active elderly (MAE), sedentary elderly (SE) (n = 109), mobility impaired elderly (MIE) (n = 43), and in adult young controls (YC) (n = 60). The ratio of Lf/Tm was calculated to obtain an ultrasound index of the loss of muscle mass associated with sarcopenia (USI). In a subsample of elderly male individuals (n = 76) in which corresponding DXA measurements were available (MAE, n = 52 and SE, n = 24), DXA-derived skeletal muscle index (SMI, appendicular limb mass/height For both young and older participants, USI values were found to be independent of sex, height and body mass. USI values were 3.70 ± 0.52 for YC, 4.50 ± 0.72 for the MAE, 5.05 ± 1.11 for the SE and 6.31 ± 1.38 for the MIE, all significantly different between each other (P < 0.0001). Based on the USI Z-scores, with reference to the YC population, the 219 elderly participants were stratified according to their muscle sarcopenic status. Individuals with USI values within a range of 3.70 < USI ≥ 4.23 were classified as non-sarcopenic (prevalence 23.7%), those with USI values within 4.23 < USI ≥ 4.76 were classified as pre-sarcopenic (prevalence 23.7%), those with USI values within 4.76 < USI ≥ 5.29 were classified as moderately sarcopenic (prevalence 15.1%), those with USI values within range 5.29 < USI ≥ 5.82 were classified as sarcopenic (prevalence 27.9%), and those with USI values >5.82 were classified as severely sarcopenic (prevalence 9.6%). The DXA-derived SMI was found to be significantly correlated with USI (r = 0.61, P < 0.0001). Notably, the USI cut-off value for moderate sarcopenia (4.76 a.u.) was found to coincide with the DXA cut-off value of sarcopenia (7.26 kg/m We propose a novel, practical, and inexpensive imaging marker of the loss of muscle mass associated with sarcopenia, called the ultrasound sarcopenic index (USI), based on changes in muscle geometric proportions. These changes provide a useful 'signature of sarcopenia' and allow the stratification of individuals according to the presence and severity of muscle sarcopenia. We are convinced that the USI will be a useful clinical tool for confirming the diagnosis of sarcopenia, of which the assessment of muscle mass is a key-component.

Sections du résumé

BACKGROUND
The assessment of muscle mass is a key determinant of the diagnosis of sarcopenia. We introduce for the first time an ultrasound imaging method for diagnosing sarcopenia based on changes in muscle geometric proportions.
METHODS
Vastus lateralis muscle fascicle length (Lf) and thickness (Tm) were measured at 35% distal femur length by ultrasonography in a population of 279 individuals classified as moderately active elderly (MAE), sedentary elderly (SE) (n = 109), mobility impaired elderly (MIE) (n = 43), and in adult young controls (YC) (n = 60). The ratio of Lf/Tm was calculated to obtain an ultrasound index of the loss of muscle mass associated with sarcopenia (USI). In a subsample of elderly male individuals (n = 76) in which corresponding DXA measurements were available (MAE, n = 52 and SE, n = 24), DXA-derived skeletal muscle index (SMI, appendicular limb mass/height
RESULTS
For both young and older participants, USI values were found to be independent of sex, height and body mass. USI values were 3.70 ± 0.52 for YC, 4.50 ± 0.72 for the MAE, 5.05 ± 1.11 for the SE and 6.31 ± 1.38 for the MIE, all significantly different between each other (P < 0.0001). Based on the USI Z-scores, with reference to the YC population, the 219 elderly participants were stratified according to their muscle sarcopenic status. Individuals with USI values within a range of 3.70 < USI ≥ 4.23 were classified as non-sarcopenic (prevalence 23.7%), those with USI values within 4.23 < USI ≥ 4.76 were classified as pre-sarcopenic (prevalence 23.7%), those with USI values within 4.76 < USI ≥ 5.29 were classified as moderately sarcopenic (prevalence 15.1%), those with USI values within range 5.29 < USI ≥ 5.82 were classified as sarcopenic (prevalence 27.9%), and those with USI values >5.82 were classified as severely sarcopenic (prevalence 9.6%). The DXA-derived SMI was found to be significantly correlated with USI (r = 0.61, P < 0.0001). Notably, the USI cut-off value for moderate sarcopenia (4.76 a.u.) was found to coincide with the DXA cut-off value of sarcopenia (7.26 kg/m
CONCLUSIONS
We propose a novel, practical, and inexpensive imaging marker of the loss of muscle mass associated with sarcopenia, called the ultrasound sarcopenic index (USI), based on changes in muscle geometric proportions. These changes provide a useful 'signature of sarcopenia' and allow the stratification of individuals according to the presence and severity of muscle sarcopenia. We are convinced that the USI will be a useful clinical tool for confirming the diagnosis of sarcopenia, of which the assessment of muscle mass is a key-component.

Identifiants

pubmed: 34060717
doi: 10.1002/jcsm.12720
pmc: PMC8350200
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

973-982

Subventions

Organisme : Medical Research Council
ID : MR/P021220/1
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Muscle Nerve. 2014 Mar;49(3):315-24
pubmed: 24122772
Age Ageing. 2014 Nov;43(6):748-59
pubmed: 25241753
J Appl Physiol (1985). 2000 Jul;89(1):81-8
pubmed: 10904038
J Physiol. 2001 Jul 15;534(Pt. 2):613-23
pubmed: 11454977
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
J Physiol. 2007 Sep 15;583(Pt 3):1079-91
pubmed: 17656438
Exp Physiol. 2004 Nov;89(6):675-89
pubmed: 15328305
Acta Physiol (Oxf). 2008 Jul;193(3):265-74
pubmed: 18266998
Muscle Nerve. 2000 Jun;23(6):851-62
pubmed: 10842260
Life (Basel). 2020 Sep 08;10(9):
pubmed: 32911678
Med Sci Sports Exerc. 2010 Sep;42(9):1644-50
pubmed: 20142771
J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):973-982
pubmed: 34060717
Exp Physiol. 2015 Oct;100(10):1159-67
pubmed: 26279270
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Am Geriatr Soc. 2002 May;50(5):889-96
pubmed: 12028177
Muscle Nerve. 2000 Nov;23(11):1647-66
pubmed: 11054744
J Appl Physiol (1985). 2008 Jul;105(1):180-6
pubmed: 18420714
Eur Geriatr Med. 2021 Feb;12(1):45-59
pubmed: 33387359
Int J Sports Med. 2003 Feb;24(2):125-30
pubmed: 12669259
J Physiol. 2007 Nov 15;585(Pt 1):241-51
pubmed: 17901116
J Biomech. 2014 Feb 07;47(3):631-8
pubmed: 24368144
J Appl Biomech. 2014 Oct;30(5):663-7
pubmed: 25010786
J Am Med Dir Assoc. 2017 Apr 1;18(4):290-300
pubmed: 28202349
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Scand J Med Sci Sports. 2018 Mar;28(3):846-853
pubmed: 28805932
Am J Epidemiol. 1998 Apr 15;147(8):755-63
pubmed: 9554417
Exerc Sport Sci Rev. 2007 Jul;35(3):126-34
pubmed: 17620931
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
J Surg Res. 2007 Oct;142(2):301-3
pubmed: 17631900
Aging Clin Exp Res. 2018 Dec;30(12):1437-1443
pubmed: 29700758
J Anat. 2014 Dec;225(6):675-84
pubmed: 25315680
J Gerontol A Biol Sci Med Sci. 2008 Aug;63(8):829-34
pubmed: 18772470
Acta Physiol Scand. 2005 Mar;183(3):291-8
pubmed: 15743389
JAMA. 2013 Oct 16;310(15):1591-600
pubmed: 24108501
Biogerontology. 2013 Jun;14(3):325-37
pubmed: 23722256
J Physiol. 1972 Jul;224(1):231-44
pubmed: 5039983
Scand J Med Sci Sports. 2019 Apr;29(4):504-514
pubmed: 30561846
Eur J Appl Physiol. 2004 Jan;91(1):116-8
pubmed: 14639480
J Cell Sci. 1971 Nov;9(3):751-67
pubmed: 5148015
J Appl Physiol (1985). 2003 Dec;95(6):2229-34
pubmed: 12844499
Antioxidants (Basel). 2019 Sep 26;8(10):
pubmed: 31561586

Auteurs

Marco Narici (M)

Department of Biomedical Sciences, University of Padova, Padova, Italy.
CIR-MYO Myology Center, University of Padua, Padua, Italy.

Jamie McPhee (J)

Department of Sport and Exercise Sciences, Manchester Metropolitan University, Manchester, UK.

Maria Conte (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Martino V Franchi (MV)

Department of Biomedical Sciences, University of Padova, Padova, Italy.

Kyle Mitchell (K)

Dorsey County Hospital NHS Foundation Trust, Dorchester, UK.

Sara Tagliaferri (S)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Elena Monti (E)

Department of Biomedical Sciences, University of Padova, Padova, Italy.

Giuseppe Marcolin (G)

Department of Biomedical Sciences, University of Padova, Padova, Italy.

Philip J Atherton (PJ)

MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research and National Institute for Health Research Nottingham Biomedical Research Centre, University of Nottingham, Derby, UK.

Kenneth Smith (K)

MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research and National Institute for Health Research Nottingham Biomedical Research Centre, University of Nottingham, Derby, UK.

Bethan Phillips (B)

MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research and National Institute for Health Research Nottingham Biomedical Research Centre, University of Nottingham, Derby, UK.

Jonathan Lund (J)

Department of Surgery and University of Nottingham School of Medicine, Royal Derby Hospital, Derby, UK.

Claudio Franceschi (C)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Marcello Maggio (M)

Department of Internal Medicine and Biomedical Sciences, Section of Geriatrics, University of Parma, Parma, Italy.

Gillian S Butler-Browne (GS)

Center for Research in Myology UMRS974, Sorbonne Université, INSERM, Myology Institute, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH